{"brief_title": "Comparative Study of Modified Release (MR) Tacrolimus/Mycophenolate Mofetil (MMF) in de Novo Kidney Transplant Recipients", "brief_summary": "The purpose of this study is to compare the safety and efficacy of tacrolimus/mycophenolate mofetil (MMF), cyclosporine/MMF and tacrolimus modified release/MMF in de novo kidney transplant recipients.", "detailed_description": "This was a 3 arm randomized, open-label, comparative, multi-center study in de novo kidney transplant recipients at 60 centers in the U.S., Canada and Brazil. The study consisted of a 1-year post-transplant efficacy and safety study with a clinical continuation phase of a minimum of 2 years or until commercial availability of tacrolimus modified release, unless the Data Safety Monitoring Board or sponsor specified otherwise.", "condition": ["Kidney Transplantation"], "intervention_type": ["Drug", "Drug", "Drug", "Drug"], "intervention_name": ["Tacrolimus Modified Release (MR)", "Tacrolimus", "cyclosporine microemulsion", "mycophenolate mofetil"], "description": ["The target range for whole blood tacrolimus trough concentrations was 7 to 16 ng/mL for days 0 through 90, and 5 to 15 ng/mL thereafter.", "The target range for whole blood tacrolimus trough concentrations was the recommended trough concentration range for Prograf: 7 to 16 ng/mL for days 0 through 90 and 5 to 15 ng/mL thereafter.", "The target range for whole blood cyclosporine trough concentrations was 125 to 400 ng/mL for days 0 through 90, and 100 to 300 ng/mL thereafter.", "Oral"], "arm_group_label": ["Tacrolimus Modified Release", "Tacrolimus", "Cyclosporine", "Tacrolimus", "Tacrolimus Modified Release", "Cyclosporine"], "other_name": ["Advagraf, FK506, FKMR, MR4, Astagraf XL", "Prograf, FK506", "Neoral, CsA", "CellCept, MMF"], "criteria": "Inclusion Criteria: - Recipient of a primary or retransplanted non-human leukocyte antigen (HLA)-identical living or non-HLA-identical cadaveric kidney transplant - Age greater or equal to 12 years Exclusion Criteria: - Recipient or donor is known seropositive for human immunodeficiency virus (HIV) - Has current malignancy or history of malignancy - Has significant liver disease - Has uncontrolled concomitant infection or any other unstable medical condition - Is receiving everolimus or enteric coated mycophenolic acid at any time during the study - Received kidney with a cold ischemia time of equal or more than 36 hours - Received kidney transplant from a cadaveric donor equal or more than 60 years of age - Received intravenous immunoglobulin (IVIG) therapy prior to randomization", "gender": "All", "minimum_age": "12 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "tacrolimus", "mesh_term": ["Tacrolimus", "Cyclosporine", "Mycophenolate mofetil", "Cyclosporins", "Mycophenolic Acid"], "id": "NCT00064701"}